We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at ...

When I undertook a sociological survey, at the age of 23 years among the Veddas of Wellassa-Bintenne in 1950, I came to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead to shareholder dilution. Learn more on SAVA stock here.

Cassava Sciences, Inc. (SAVA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...

A research collaboration between The University of Warwick, the Smithsonian Institution and Embrapa (Brazilian agricultural ...

“Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, in late first-quarter/early second-quarter 2025.

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative diseases, such as Alzheimer’s disease (AD), is expected to report ...

Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s ...